Surveillance of Resistance to New Antibiotics in an Era of Limited Treatment Options

被引:2
作者
Morel, Chantal M. [1 ,2 ,3 ]
de Kraker, Marlieke E. A. [2 ,4 ]
Harbarth, Stephan [2 ,4 ,5 ]
机构
[1] Univ Geneva Hosp, Geneva, Switzerland
[2] Fac Med, Geneva, Switzerland
[3] Univ Hosp Bonn, Inst Hyg & Publ Hlth, Bonn, Germany
[4] Univ Geneva Hosp, Infect Control Programme, Geneva, Switzerland
[5] Univ Geneva Hosp, WHO Collaborating Ctr Patient Safety, Geneva, Switzerland
基金
瑞士国家科学基金会;
关键词
resistance surveillance; antibiotics; antimicrobial resistance; antimicrobial susceptibility; early warning systems; CARE-ASSOCIATED INFECTIONS; ANTIMICROBIAL RESISTANCE; STAPHYLOCOCCUS-AUREUS; RECOMMENDATIONS; SUSCEPTIBILITY; PNEUMONIAE; BACTERIA; SYSTEMS; EUROPE;
D O I
10.3389/fmed.2021.652638
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As with any health threat, our ability to respond to the emergence and spread of antimicrobial resistance depends on our ability to understand the scale of the problem, magnitude, geographical spread, and trends over time. This is especially true for resistance emergence to newer antibiotics coming to the market as last-resort treatments. Yet current antibiotic surveillance systems are limited to monitoring resistance to commonly prescribed drugs that have been on the market for a long time. This qualitative study determined the essential elements and requirements of antimicrobial resistance surveillance for new antibiotics based on literature review, interviews and expert consensus. After an extensive mapping exercise, 10 experts participated in a modified Delphi consultation to identify consensus on all elements required for surveillance of resistance to novel antibiotics. The main findings indicate that there is a need for a two-phase system; an early alert system transitioning to routine surveillance, led by the public sector to gather and share essential data on resistance to newer antibiotics in a transparent manner. The system should be decentralized, run largely from national level, but be coordinated by an arm of an existing international public health institution. Priority should be given to monitoring emergence of resistance among already multi-drug resistant pathogens causing infections, over a broader selection of pathogens to maximize clinical impact. In conclusion, we cannot rely on current AMR surveillance systems to monitor resistance emergence to new antibiotics. A new, public system should be set-up, starting with a focus on detecting resistance emergence, but expanding to a more comprehensive surveillance as soon as there is regional spread of resistance to the new antibiotic. This article provides a framework based on expert agreement, which could guide future initiatives.
引用
收藏
页数:10
相关论文
共 47 条
  • [21] Supranational surveillance of antimicrobial resistance: The legacy of the last decade and proposals for the future
    Giske, Christian G.
    Cornaglia, Giuseppe
    [J]. DRUG RESISTANCE UPDATES, 2010, 13 (4-5) : 93 - 98
  • [22] Global Antimicrobial Resistance and Use Surveillance System (GLASS), 2020, EARL IMPL REP
  • [23] Standardization and quality assurance for antimicrobial resistance surveillance of Streptococcus pneumoniae and Staphylococcus aureus within the European Antimicrobial Resistance Surveillance System (EARSS)
    Goettsch, W
    Bronzwaer, SLAM
    de Neeling, AJ
    Wale, MCJ
    Aubry-Damon, H
    Olsson-Liljequist, B
    Sprenger, MJW
    Degener, JE
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2000, 6 (02) : 59 - 63
  • [24] Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study
    Grundmann, Hajo
    Glasner, Corinna
    Albiger, Barbara
    Aanensen, David M.
    Tomlinson, Chris T.
    Tambic Andrasevic, Arjana
    Canton, Rafael
    Carmeli, Yehuda
    Friedrich, Alexander W.
    Giske, Christian G.
    Glupczynski, Youri
    Gniadkowski, Marek
    Livermore, David M.
    Nordmann, Patrice
    Poirel, Laurent
    Rossolini, Gian M.
    Seifert, Harald
    Vatopoulos, Alkiviadis
    Walsh, Timothy
    Woodford, Neil
    Monnet, Dominique L.
    Apfalter, Petra
    Hartl, Rainer
    Glupczynski, Youri
    Huang, Te-Din
    Strateva, Tanya
    Marteva-Proevska, Yuliya
    Andrasevic, Arjana Tambic
    Butic, Iva
    Pieridou-Bagatzouni, Despo
    Maikanti-Charalampous, Panagiota
    Hrabak, Jaroslav
    Zemlickova, Helena
    Hammerum, Anette
    Jakobsen, Lotte
    Ivanova, Marina
    Pavelkovich, Anastasia
    Jalava, Jari
    Osterblad, Monica
    Vaux, Sophie
    Dortet, Laurent
    Kaase, Martin
    Gatermann, Soeren G.
    Vatopoulos, Alkiviadis
    Tryfinopoulou, Kyriaki
    Toth, Akos
    Janvari, Laura
    Boo, Teck Wee
    McGrath, Elaine
    Pantosti, Annalisa
    [J]. LANCET INFECTIOUS DISEASES, 2017, 17 (02) : 153 - 163
  • [25] A framework for global surveillance of antibiotic resistance
    Grundmann, Hajo
    Klugman, Keith P.
    Walsh, Timothy
    Ramon-Pardo, Pilar
    Sigauque, Betuel
    Khan, Wasif
    Laxminarayan, Ramanan
    Heddini, Andreas
    Stelling, John
    [J]. DRUG RESISTANCE UPDATES, 2011, 14 (02) : 79 - 87
  • [26] Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum
    Huttner, Angela
    Harbarth, Stephan
    Carlet, Jean
    Cosgrove, Sara
    Goossens, Herman
    Holmes, Alison
    Jarlier, Vincent
    Voss, Andreas
    Pittet, Didier
    [J]. ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2013, 2
  • [27] Evolving concepts of pharmaceutical company-sponsored surveillance studies
    Koeth, LM
    Miller, LA
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 : S279 - S282
  • [28] Leclerc QJ., 2020, Wellcome Open Res, V4, P140, DOI DOI 10.12688/WELLCOMEOPENRES.15477.2
  • [29] THE ROLE OF THE PHARMACEUTICAL ANIMAL HEALTH INDUSTRY IN POSTMARKETING SURVEILLANCE OF RESISTANCE
    LENS, S
    [J]. VETERINARY MICROBIOLOGY, 1993, 35 (3-4) : 339 - 347
  • [30] Global antimicrobial resistance alerts and implications
    Levy, SB
    O'Brien, TF
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 : S219 - S220